Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | MPL | P40238 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2678408 | 0.79 | NOS1 (0.52) | NOS1MPLHSD17B10HPGDMAPT | |
| SCHEMBL5174730 | 0.76 | COMT (0.46) | HSD17B10HPGDMAPTGAAALDH1A1 | |
| SCHEMBL1897569 | 0.76 | ALDH1A1 (0.39) | NOS1MPLHSD17B10HPGDGAA | |
| SCHEMBL20907837 | 0.74 | MPL (0.42) | NOS1MPLHSD17B10HPGDGAA | |
| Ammonia Solution, Strong SCHEMBL29243356 | 0.74 | COMT (0.44) | MAPTGAAALDH1A1SMN1; SMN2COMT | |
| SCHEMBL30327992 | 0.74 | COMT (0.33) | MAPTCOMT | |
| SCHEMBL26747517 | 0.74 | COMT (0.33) | MAPTALDH1A1COMT | |
| SCHEMBL12086420 | 0.74 | HPGD (0.37) | NOS1MPLHSD17B10HPGDALDH1A1 | |
| SCHEMBL10699580 | 0.73 | ALDH1A1 (0.34) | HPGDMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL4589608 | 0.73 | ALDH1A1 (0.37) | NOS1MPLHSD17B10HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | claimed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | claimed |
| WO-2025125665-A1 | FURTHER SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-06-19 | — | — | WO | disclosed |
| US-20240208961-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-20240208961-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-20240208961-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2024-06-27 | — | — | US | disclosed |
| WO-2024112894-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2023141262-A1 | BAX ACTIVATORS AND USE THEREOF | IPSEN PHARMA S.A.S. (FR) | 2023-07-27 | — | — | WO | disclosed |
| US-10653681-B2 | Analgesic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-7576115-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| CN-101448800-A | Novel compounds as cannabinoid receptor ligands and uses thereof | ABBOTT LAB (US) | 2009-06-03 | — | — | CN | disclosed |
| CN-101356161-A | Heterocyclic CETP inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-01-28 | — | — | CN | disclosed |
| US-7351841-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-7351841-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | NOS1 1328/4885MPL 32/4885HSD17B10 824/4885 |
| US-20240208961-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | NOS1 4145/4885MPL 3580/4885HSD17B10 4204/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | NOS1 2398/4885MPL 3310/4885HSD17B10 2243/4885 |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | OPRL1, OPRK1, OPRD1 | NOS1 233/4885MPL 3260/4885HSD17B10 2979/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | NOS1 2586/4885MPL 3256/4885HSD17B10 2258/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | NOS1 2398/4885MPL 3310/4885HSD17B10 2243/4885 |
| US-10653681-B2 | Analgesic compounds | OPRK1, OPRL1, OPRM1 | NOS1 1378/4885MPL 3829/4885HSD17B10 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.